The dopamine radioreceptor assay--a clinical application.

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Neuroscience

Background:

• Haloperidol (Haldol) is a widely used antipsychotic medication.
• Assessing bioequivalence between different dosage forms is crucial for ensuring therapeutic consistency.
• Previous studies have established the efficacy and safety profile of haloperidol.

Purpose of the Study:

• To evaluate the bioequivalence of a new 20-mg haloperidol dosage form compared to two 10-mg tablets.
• To determine if the new dosage form maintains the same clinical effect and safety profile as the existing formulation.
• To assess the utility of a dopamine receptor blocking assay in evaluating neuroleptic equivalence.

Main Methods:

• A counterbalanced bioequivalence study design was employed.
• Participants received a fixed once-daily dose of 20 mg haloperidol in either the new dosage form or two 10-mg tablets for four weeks.
• Behavioral changes were monitored, and a dopamine receptor blocking assay was utilized to assess plasma neuroleptic equivalence.

Main Results:

• No significant clinical differences were observed between the new 20-mg haloperidol dosage form and two 10-mg tablets.
• Absence of significant behavioral changes further supported the clinical equivalence of both haloperidol formulations.
• The dopamine receptor blocking assay indicated no significant difference in plasma neuroleptic equivalence between the dosage forms.

Conclusions:

• The new 20-mg haloperidol dosage form is bioequivalent to two 10-mg tablets.
• The dopamine receptor blocking assay shows promise for clinical applications in adjusting neuroleptic drug dosages and monitoring drug usage.
• Findings support the use of the new haloperidol formulation for consistent therapeutic outcomes.